SeraCare允许加州大学技术来开发无创产前检测相关材料

  近日，SeraCare生命科学同加尼弗尼亚大学宣布了一项许可协议，即利用21、18和13三体染色体滋养层细胞系材料为非侵入性产前染色体异常检测技术开发相关的材料。
  在进行了这项协议后，SeraCare生命科学就发起了一项早期访问计划，旨在开发循环的无细胞的胎儿DNA T21、T18、T13非整倍体的相关材料。
  作为这项协议的一部分，位于亚特兰大的SeraCare生命科学公司将会给加利福尼亚大学支付一笔未公开金额的前期费用，而且加利福尼亚大学也会接受另外的资助来进行某些商业领域的发展。
  随着基于新一代测序技术的无创产前检测技术快速发展，Cowen and Company公司医药技术经理Doug Schenkel这周已经瞅准了100亿的无创产前检测技术的全球市场机会，而SeraCare表示，目前迫切需要相关的材料来确保无创产前检测技术的准确性。
  最后该公司在一份声明中表示，这对于实验室级别进行这样的操作尤其重要，而且还需要进行培训、验证、优化并且监测新一代测序技术及微阵列分析的业绩变化情况。 （转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

SeraCare Licenses UCSF Technology to Develop NIPT Reference Materials

 SeraCare Life Sciences today announced a licensing agreement with the University of California, San Francisco for the use of its trisomy 21, 18, and 13 trophoblast cell line materials to develop reference materials for non-invasive prenatal testing of chromosomal abnormalities. 

In conjunction with the deal, SeraCare has launched an early access program for circulating, cell-free fetal DNA T21, T18, and T13 aneuploidy reference materials developed with the UCSF technology. 

As part of the agreement, Atlanta-based SeraCare will pay UCSF an upfront fee of an undisclosed amount. The university will also receive additional payments based on the achievement of certain development and commercial milestones. 

With next-generation sequencing-based NIPT methods rapidly growing in popularity — Cowen & Co.'s Doug Schenkel this week pegged the global market opportunity for NIPT at $10 billion, and the US opportunity at $1.5 billion — SeraCare cited a need for reference materials to ensure accuracy of the technology. 

"This is especially critical as labs scale up their operation and need to train, validate, optimize, and monitor ongoing performance of their next-generation sequencing or microarray assays," the firm said in a statement.